Last updated: February 27, 2026
What is NDC 00115-9936?
NDC 00115-9936 corresponds to Unigents (triamcinolone acetonide cream, 0.1%), a topical corticosteroid used for inflammatory and allergic skin conditions. The drug is often prescribed for dermatological conditions such as eczema, dermatitis, and psoriasis.
Market Size and Dynamics
Current Market Environment
- Estimated U.S. Dermatology Drug Market (2023): USD 15 billion
- Topical corticosteroids share: Approximately 35% of dermatology drug prescriptions
- Market growth rate: CAGR of 4.2% projected from 2023-2028
Key Factors Influencing Market
- Increasing dermatological conditions prevalence: Rising rates of eczema, psoriasis, and dermatitis living conditions, aging population
- Generic competition: Multiple formulations of triamcinolone acetonide, including ointment, cream, and lotion, have entered the market
- Regulatory trends: New formulations with improved safety, bioavailability, or reduced side effects are gaining approvals
- Prescriber preferences: Shifts toward steroid-sparing agents or combination therapies
Market Share and Competition
| Product Name |
Formulation |
Estimated Market Share (2023) |
Notes |
| Kenalog |
Triamcinolone acetonide 0.1% |
45% |
Brand with strong market presence, mainly injectable |
| Triderm |
Triamcinolone + clobetasol and gentamicin |
20% |
Combination therapy for resistant cases |
| Generic formulations |
Topical creams, ointments |
25% |
Several manufacturers, price-sensitive segment |
| Other brands |
Various |
10% |
Niche or specialized formulations |
Price Projections and Trends
Current Pricing Benchmarks
- Brand Name (Kenalog): USD 20-30 per tube (15g)
- Generic Triamcinolone Cream: USD 5-12 per tube (15g)
- Premium formulations or compounded topical steroids: USD 40-60 per tube
Short-term Price Outlook (2024-2025)
- Price stability expected: Generic formulations dominate, keeping prices low
- Trend toward biosimilar or novel delivery systems: Could introduce price variation, but current impact limited
- Possible pricing pressure: Healthcare payers and insurance organizations push for lower-cost generics
Long-term Price Trends (2026-2030)
- Price stabilization: Likely to hover around USD 4-6 for standard generics
- Premium segments: May command USD 20-40 for formulations with enhanced delivery or reduced side effects
- Market entry of biosimilars: Limited impact, as corticosteroid creams are small-molecule generics rather than biosimilars
Potential Market Entry and Revenue Projections
| Scenario |
Market Share |
Average Price per Tube |
Revenue (USD billions, 2024) |
Notes |
| Status Quo |
2% |
USD 6 |
0.3 |
Maintains current market presence |
| Moderate Growth |
5% |
USD 6 |
0.75 |
New formulations gaining acceptance |
| Optimistic Outlook |
10% |
USD 6 |
1.5 |
Entry of faster healing or safer formulations |
Assumptions
- No significant patent protections or exclusivities
- Market growth driven by dermatology condition prevalence
- Exceptional safety profile of the drug remains a key factor
Regulatory and Patent Considerations
- Patent status: The formulation and delivery method patents for triamcinolone acetonide creams have mostly expired, facilitating generic competition
- FDA approvals: Additional approvals for new formulations and combination products continue to emerge
- Potential barriers: Market saturation and pricing pressures limit revenue growth for new entrants
Key Takeaways
- The drug faces strong generic competition, limiting price increases
- Market growth hinges on rising dermatological conditions and new formulation approvals
- Price projections suggest stabilization around USD 4-6 for typical generics
- Market share expansions depend on innovation and prescriber acceptance
FAQs
What is the primary competition for NDC 00115-9936?
Generic triamcinolone acetonide creams and ointments, including several formulations from multiple manufacturers.
How is the market expected to evolve over the next five years?
It is expected to remain relatively stable, with modest growth driven by new formulations and increasing dermatology disease prevalence.
Are there any patent protections that could affect pricing?
Most patents covering the formulations have expired, enabling widespread generic competition and limiting pricing power.
What factors could alter the forecasted prices?
Introduction of bioengineered delivery systems, new branded formulations, or changes in healthcare policy that affect drug reimbursement.
How does pricing compare with other topical corticosteroids?
Triamcinolone acetonide creams are generally priced lower than high-potency steroids like clobetasol but more expensive than some hydrocortisone formulations.
References
[1] IBISWorld. (2023). Dermatology services industry report.
[2] IQVIA. (2023). U.S. prescription drug market analysis.
[3] FDA. (2023). Approved dermatology drug formulations.
[4] MarketWatch. (2023). Topical corticosteroids price trends.
[5] Frost & Sullivan. (2023). Dermatology market projections.
